<?xml version="1.0"?>
<Articles JournalTitle="Journal of Arthropod-Borne Diseases">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Journal of Arthropod-Borne Diseases</JournalTitle>
      <Issn>2322-1984</Issn>
      <Volume>18</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>09</Month>
        <Day>30</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Fatal Crimean-Congo Hemorrhagic Fever with an Atypical Clinical Course during the COVID-19 Pandemic</title>
    <FirstPage>276</FirstPage>
    <LastPage>280</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Mustafa</FirstName>
        <LastName>Arslan</LastName>
        <affiliation locale="en_US">Amasya University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Turkey</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>05</Month>
        <Day>01</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2025</Year>
        <Month>03</Month>
        <Day>28</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: Crimean-Congo hemorrhagic fever (CCHF) is a viral zoonotic disease characterized by high fever, bleeding manifestations, and a high mortality rate. Most patients begin to experience bleeding 5 to 7 days after the onset of the illness, usually while hospitalized. This report highlights that even though patients may develop shock and multi-organ failure, there might be no visible signs of bleeding until shortly before death.
Methods: This case report describes a 42-year-old male patient with a confirmed diagnosis of CCHF via RT-PCR, who died despite intensive care treatment. Despite receiving intensive care treatment, he did not respond to the septic shock therapy and unfortunately passed away within a few hours. The diagnosis of the disease was made by the reference la&#xAD;boratory with a positive reverse transcriptase-polymerase chain reaction (RT-PCR) test for CCHF.
Results: In this case, the patient exhibited no visible signs of bleeding, such as hematemesis, melena, or gross hematuria, despite being in shock. While CCHF mortality (5&#x2013;30%) typically occurs during the 3&#x2013;5-day hemorrhagic phase, this patient died suddenly due to massive intra-abdominal bleeding, skipping the typical bleeding phase.
Conclusion: Clinicians should consider that individual differences may be seen in the clinical course of CCHF disease. In addition, the Coronavirus Disease-2019 (COVID-19) pandemic was experienced worldwide when the patient ap&#xAD;plied. Given the overlapping initial symptoms of COVID-19 and CCHF, clinicians should prioritize differential diagnosis, es-pecially during the COVID-19 pandemic. During the COVID-19 pandemic, diagnostic delays may occur in the manage-ment of CCHF, particularly due to resource allocation.</abstract>
    <web_url>https://jad.tums.ac.ir/index.php/jad/article/view/1641</web_url>
    <pdf_url>https://jad.tums.ac.ir/index.php/jad/article/download/1641/667</pdf_url>
  </Article>
</Articles>
